Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.

@article{Giorgi2012SunitinibAF,
  title={Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.},
  author={Ugo De Giorgi and Karim Rihawi and Giovanni Lo Re and Teodoro Sava and Cristina Masini and Michele Aieta and Andrea Camerini and Giuseppe Fornarini and Luciano Burattini and Fabio De Vincenzo and Giovanni Rosti and Vittorio D. Ferrari and Luca Moscetti and Vincenzo Emanuele Chiuri and Stefano Luzi Fedeli and Emanuela Scarpi and Umberto Basso},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 5_suppl},
  pages={411}
}
411 Background: Many medical oncologists are still reluctant to use the standard sunitinib regimen in older patients (pts) with metastatic renal cell cancer (mRCC) because of concerns about tolerance. We assessed the routine use of first-line sunitinib in mRCC pts aged ≥70 yrs. METHODS We reviewed the clinical files of 154 pts aged ≥70 yrs with mRCC treated with first-line sunitinib in sixteen Italian Oncology Units from February 2006 to April 2011. Sunitinib 50 mg/d 4 wk on/2 wk off was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Optimal management of renal cell carcinoma in the elderly: a review

Clinical interventions in aging • 2013
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…